Professor James is Professor of Urological Oncology at the Institute of Cancer Research and an Honorary Consultant at the Royal Marsden Hospital in London. He was previously Professor of Clinical Oncology in Birmingham up until 2019. Prof. James is internationally renowned for his work in Urological Cancer, particularly on the ground-breaking STAMPEDE trial, which has been used to evaluate, to date, 10 different therapies for advanced prostate cancer in more than 11,000 men. Results from STAMPEDE with docetaxel 1,2 and abiraterone 3,4 and prostate radiotherapy 5 have shown that big survival gains can be made by using existing treatments in novel settings. In the bladder cancer field Prof James has led a series of trials of chemoradiotherapy that demonstrated that low dose synchronous chemotherapy reduced invasive bladder cancer relapse rates by 43%, published in the New England Journal of Medicine 6. Key publications: N D James \t1.\tVale CL, Burdett S, Rydzewska LH, et al: Lancet Oncol 17:243-56, 2016 \t2.\tJames ND, Sydes MR, Clarke NW, et al: Lancet 387:1163-77, 2016 \t3.\tRydzewska LHM, Burdett S, Vale CL, et al: Eur J Cancer 84:88-101, 2017 \t4.\tJames ND, de Bono JS, Spears MR, et al: N Engl J Med 377:338-351, 2017 \t5.\tParker CC, James ND, Brawley CD, et al: Lancet, 2018 \t6.\tJames ND, Hussain SA, Hall E, et al: N Engl J Med 366:1477-88, 2012